Topic: Interactions Of HBV Infection With MASLD Pathobiology
A Special Issue of Metabolism and Target Organ Damage
ISSN 2769-6375 (Online)
Submission deadline: 15 Mar 2025
Guest Editor(s)
Special Issue Introduction
The complex interplay between the Hepatitis B Virus (HBV) life cycle and metabolic dysfunction-associated steatotic liver disease (MASLD) is intriguing and incompletely understood.
On the one hand, evidence suggests that hepatic steatosis, through interactions between HBV and lipid droplets, may suppress HBV replication. This is associated with higher rates of HBsAg seroclearance and seroconversion in treatment-naive HBeAg-negative subjects, potentially reducing liver injury and improving certain hepatic and cardiovascular outcomes.
On the other hand, MASLD linked to HBV infection can exacerbate fibrotic progression and increase the risks of diabetes and hepatocellular carcinoma due to metabolic dysfunction, especially in individuals with severe steatosis.
This enigmatic body of evidence deserves full characterization. Therefore, the present Special Issue invites original studies and review articles that explore all aspects of the interactions between HBV and MASLD pathobiology, from molecular analysis to clinical epidemiology, prognostication, and management.
On the one hand, evidence suggests that hepatic steatosis, through interactions between HBV and lipid droplets, may suppress HBV replication. This is associated with higher rates of HBsAg seroclearance and seroconversion in treatment-naive HBeAg-negative subjects, potentially reducing liver injury and improving certain hepatic and cardiovascular outcomes.
On the other hand, MASLD linked to HBV infection can exacerbate fibrotic progression and increase the risks of diabetes and hepatocellular carcinoma due to metabolic dysfunction, especially in individuals with severe steatosis.
This enigmatic body of evidence deserves full characterization. Therefore, the present Special Issue invites original studies and review articles that explore all aspects of the interactions between HBV and MASLD pathobiology, from molecular analysis to clinical epidemiology, prognostication, and management.
Submission Deadline
15 Mar 2025
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/mtod/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mtod&SpecialIssueId=mtod240808
Submission Deadline: 15 Mar 2025
Contacts: Lily Luo, Assistant Editor, lily@oae-publish.com
